Apimeds Pharmaceuticals US, Inc
APUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $99 | $368 | $490 |
| G&A Expenses | $1,275 | $649 | $272 | $530 |
| SG&A Expenses | $1,275 | $649 | $272 | $530 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,275 | $747 | $640 | $1,019 |
| Operating Income | -$1,275 | -$747 | -$640 | -$1,019 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$115 | -$30 | -$29 | -$7 |
| Pre-Tax Income | -$1,390 | -$778 | -$669 | -$1,026 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,390 | -$778 | -$669 | -$1,026 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.068 | -0.058 | -0.089 |
| % Growth | -77.8% | -16.4% | 34.8% | – |
| EPS Diluted | -0.11 | -0.061 | -0.053 | -0.081 |
| Weighted Avg Shares Out | 11,527 | 11,527 | 11,527 | 11,527 |
| Weighted Avg Shares Out Dil | 12,693 | 12,693 | 12,693 | 12,693 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $8 | $0 | $0 |
| Interest Expense | $118 | $38 | $29 | $7 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,272 | -$740 | -$640 | -$1,019 |
| % Margin | – | – | – | – |